Clinical efficacy and adverse effects of nimodipine combined with rivastigmine in the treatment of senile vascular dementia / 中国基层医药

ABSTRACT

Objective To learn the clinical efficacy and adverse effects of nimodipine combined with riva stigmine in the treatment of senile vascular dementia,and to provide effective treatment for the disease.Methods 151 elderly patients with senile vascular dementia were randomly divided into observation group (78 cases) and control group (73 cases) by using the random number table method.The control group was given nimodipine,and the observation group was given nimodipine combined with rivastigmine.The cognitive function was assessed by mini mental state examination(MMSE) scale,clinical dementia rating (CDR) scale was used to evaluate the degree of dementia,and activity of daily living (ADL) scale was used to evaluate the ability of daily activities.P300 test was performed before and after treatment for 12 weeks,and latency period (P300-PL) and amplitude (P300-A) of P300 were determined.The adverse drug reactions of the two groups were observed during the treatment period.Results After 12 weeks of treatment,the MMSE scores of the two groups were higher than before treatment,the CDR,ADL scores of the two groups were significantly lower than before treatment (t =8.353,18.289,6.627,2.463,10.681,5.201,all P ＜ 0.05).After 12 weeks of treatment,the MMSE score of the observation group [(23.17 ±3.95) points] was significantly higher than that of the control group [(19.88 ± 4.43) points],the ADL,CDR scores of the observation group were (1.47 ± 0.26) points and (39.87 ± 7.43) points,which were significantly lower than (1.80 ± 0.34) points,(41.16 ± 6.40) points of the control group (t =4.823,6.725,5.278,all P ＜ 0.05).After 12 weeks of treatment,the P300-PL of the two groups were lower than those before treatment,the P300-A of the two groups were significantly higher than those before treatment (t =12.051,6.429,2.477,2.104,all P ＜ 0.05).After 12 weeks of treatment,P300-PL of the observation group [(321 ± 39)ms] was significantly lower than that of control group [(356 ± 44) ms] (t =5.180,P ＜ 0.05).In the course of treatment,the incidence rate of adverse reaction of the control group was 9.59％,that of the observation group was 11.54％,there was no statistically significant difference (x2 =0.151,P ＞ 0.05).Conclusion Nimodipine combined with rivastigrnine can effectively treat senile vascular dementia,improve cognitive function,degree of dementia and daily activity ability of patients,the incidence rate of adverse drug reaction is low,and the therapeutic method is well tolerated with good clinical application value.